BathonJ.M., MartinR.W., FleischmannR.M.A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med2000; 343: 1586–1593.
3.
MeaseP.J., GoffeB.S., MetzJ.Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. The Lancet2000; 345: 385–390.
4.
LovellD.J., GianniniE.H., ReiffA.Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med2000; 342: 763.
5.
LevineB., KalmanJ., MayerL.Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med1990; 323: 236–241.
6.
Torre-AmioneG., KapadiaS., LeeJ.Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation1996; 93: 704–711.
7.
DeswalA., BozkurtB., SetaY.Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation1999; 99: 3224–3226.
8.
BozkurtB., Torre-AmioneG., WarrenM.S.Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation2001; 103: 1044–1047.
9.
FichtlschererS., RossigL., BreuerS.Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation2001; 104: 3023–3025.
10.
AnkerS.D., and CoatsA.J.S.How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE and ATTACH. Int J Cardiology2002; 86: 123–130.
11.
KwonH.J., CoteT.R., CuffeM.S.Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Int Med2003; 138: 807–812.
12.
WolfeF., and MichaudK.Heart failure in rheumatoid arthritis: rates, predictors and the effect of anti-tumor necrosis factor therapy. Am J Med2004; 116: 305–311.
13.
ZhengL., FisherG., MillerR.E.Induction of apoptosis in mature T cells by tumour necrosis factor. Nature1995; 55: 906–907.
14.
BecherB., BlainM., GlacominiP.S.Inhibition of TH1 polarization by soluable TNF receptor is dependent on antigen presenting cell derived IL-12. J Immunol1999; 162: 684–688.
15.
SmithK.J., and SkeltonH.G.Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor-alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol2001; 45: 953–956.
16.
BurgeD.Etanercept and squamous cell carcinoma. J Am Acad Dermatol2003; 49: 358.
17.
BrownS.L., GreeneM.H., GershonS.K.Tumor necrosis factor antagonist therapy and lymphoma development: 26 cases reported to the U.S. Food and Drug Administration. Arth Rheum2002; 46: 3151–3158.
18.
ThomasE., BrewsterD.H., BlackR.J.Risk of malignancy among patients with rheumatic conditions. Int J Cancer2000; 88: 497–502.
19.
BernsteinC.N., BlanchardJ.F., KliewerE.Cancer risk in patients with inflammatory bowel disease: a population based study. Cancer2001; 91: 854–862.
20.
KinlenL.Immunosuppressive therapy and acquired immunological disorders. Cancer Res1992; 52 Suppl: 5474–5476.
21.
DayR.Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. The Lancet2002; 359: 540–541.
22.
VidalF., Fontova, and RichartC.Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med2003; 139: W63.
23.
SteensmaD.P., MesaR.A., LiC.Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood2002; 99: 2252–2254.
24.
KaplanG., and FreedmanV.H.The role of cytokines in the immune response to tuberculosis. Res Immunol1996; 147: 565–572.
25.
SaundersB.M., and CooperA.M.Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol2000; 78: 334–341.
26.
MohanV.P., ScangaC.A., YuK.Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun2001; 69: 1847–1855.
27.
GardamM.A., KeystoneE.D., MenziesAnti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. The Lancet Inf Dis2003; 3: 148–155.
28.
KeaneJ., GershonS., WiseR.P.Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med2001; 345: 1098–1104.
29.
Tuberculosis Fact Sheet. American Lung Association. November 2003.
30.
SelmajK., RaineC.S., CannellaB.Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invet1991; 87: 949–954.
SelmajK., RaineC.S., CrossA.H.Anti-tumor necrosis factor therapy abrogates human demyelination. Ann Neurol1991; 30: 694–700.
33.
Van OostenB.W., BarkhofF., TruyenL.Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology1996; 47: 1531–1534.
34.
RobinsonW.H., GenoveseM.C., and MorelandL.W.Demyelinating and neurologic events reports in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?Arth Rheum2001; 44: 1977–1983.
35.
AmasonB.G.W.(Lenercept Multiple Sclerosis Study Group). TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology1999; 53: 457–465.
36.
SciotteN.L., and VoskuhlR.R.Onset of multiple sclerosis associated with anti-TNF therapy. Neurology2001; 57: 1885–1888.
37.
MohanN., EdwardsE.T., CuppsT.R.Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arth Rheum2001; 44: 2862–2869.
38.
ShakoorN., MichalskaM., HarrisC.A.Drug-induced systemic lupus erythematosis associated with etanercept therapy. The Lancet2002; 359: 579–580.
